For healthcare professionals only

Letters Return of the postcode lottery

Opportunity cost of the Cancer Drugs Fund

BMJ 2011; 342 doi: (Published 01 February 2011) Cite this as: BMJ 2011;342:d622
  1. Jonathan Howell, consultant in public health1
  1. 1West Midlands Specialised Commissioning Team, Birmingham B16 9LD, UK
  1. jon.howell{at}

Anyone involved with the Interim Cancer Drugs Fund (ICDF) will recognise the inconsistencies and contradictions in trying to make it work for drugs with poor clinical effectiveness.1 As an adviser to the regional ICDF clinical panel, I watch oncologists struggle with the poor quality clinical evidence on the proposed drugs. Many …

View Full Text

Log in

Log in through your institution


* For online subscription